Pink eye, also known as conjunctivitis, is a common and highly contagious eye infection characterized by inflammation of the conjunctiva – the thin, clear tissue that lines the inside of the eyelid and covers the whites of the eyes. This condition earns its name due to the telltale symptom it presents: reddish or pink discoloration in one or both eyes. Pink eye can be caused by several factors including bacterial or viral infections, allergies, irritants like smoke or chemicals, and even certain sexually transmitted diseases. Regardless of its origins, pink eye typically manifests with uncomfortable symptoms such as itching, burning sensations, excessive tearing, or discharge which may lead to crusting around the eyes. While proper hygiene practices such as handwashing and avoiding touching your face can help prevent this ailment from spreading further among individuals in close proximity – particularly in places like schools or offices where transmission is swift – timely medical intervention remains crucial to alleviate discomfort and prevent prolonged recuperation periods associated with this common ocular affliction.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Review looks at potential treatment targets in the tumor microenvironment.
3.
Even when they are not paying attention, children are still learning.
4.
The Benefits of Exercise for Substance Use Disorders.
5.
The top three drugs for multiple myeloma treatment upfront are four.
1.
The New Era of Oncology: Key Updates and Clinical Insights
2.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
3.
Decoding Granular Cell Tumor: What You Need to Know
4.
Subchorionic Hematoma: Causes, Symptoms, and Treatment
5.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation